<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="85621">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01845350</url>
  </required_header>
  <id_info>
    <org_study_id>STR-M2-2013</org_study_id>
    <nct_id>NCT01845350</nct_id>
  </id_info>
  <brief_title>Safety of Autologous M2 Macrophage in Treatment of Non-Acute Stroke Patients</brief_title>
  <official_title>Safety and Feasibility of Autologous M2 Macrophage Transplantation in Treatment of Non-Acute Stroke Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Siberian Branch of the Russian Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Siberian Branch of the Russian Academy of Medical Sciences</source>
  <oversight_info>
    <authority>Russia: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether M2 macrophages are safe and feasible in
      the treatment of non-acute stroke patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our primary hypothesis is that autologous M2 macrophage transplantation via intrathecal
      introduction is feasible and safe after non-acute stroke. Our secondary hypothesis is that
      autologous M2 macrophage transplantation is associated with improved neurological outcome
      after non-acute stroke
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The number of patients with severe adverse events</measure>
    <time_frame>1-3 days, 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Occurence of severe adverse events including mortality, neurological worsening and seizures</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of functional outcome in National Institutes of Health Stroke Scale (NIHSS)</measure>
    <time_frame>1-3 days, 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Barthel Index</measure>
    <time_frame>1-3 days, 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in modified Rankin scale</measure>
    <time_frame>1-3 days, 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of patients with recurrent vascular episodes</measure>
    <time_frame>1-3 days, 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Ischemic Stroke</condition>
  <condition>Hemorrhagic Stroke</condition>
  <arm_group>
    <arm_group_label>M2 macrophages</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>M2 macrophage introduction</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>M2 macrophage introduction</intervention_name>
    <description>Generation of autologous M2 macrophages from peripheral blood of non-acute stroke patients
Intrathecal introduction of autologous M2 macrophages</description>
    <arm_group_label>M2 macrophages</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Computed tomography confirmed ischemic or hemorrhagic stroke

          -  Duration since stroke onset more than 3 and less than 12 months

          -  Age between 18 and 75 years old

          -  Persistent neurological deficits more than 4 points in NIHSS stroke scale

          -  Signed informed consent

        Exclusion Criteria:

          -  The history of previous stroke

          -  Seizures

          -  Thrombophilias or primary hematological diseases

          -  Malignancy

          -  Hepatic or renal dysfunctions

          -  Hemodynamic or respiratory instability

          -  Autoimmune disease

          -  HIV or uncontrolled bacterial, fungal, or viral infections

          -  Pregnancy

          -  Participation in other clinical trials
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elena R. Chernykh, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Research Institute of Clinical Immunology, Russian Academy of Medical Sciences (Siberian Branch)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nataliya M Starostina, MD</last_name>
    <phone>+7(383)228-27-41</phone>
    <email>starostina48@bk.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ekaterina Y Shevela, MD</last_name>
    <phone>+7(383)236-03-29</phone>
    <email>shevelak@mail.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Research Institute of Clinical Immunology, Russian Academy of Medical Sciences (Siberian Branch)</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630099</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena R Chernykh, MD, PhD</last_name>
      <phone>+7(383)236-03-29</phone>
      <email>ct_lab@mail.ru</email>
    </contact>
    <contact_backup>
      <last_name>Ekaterina Y Shevela, MD</last_name>
      <phone>+7(383)236-03-29</phone>
      <email>shevelak@mail.ru</email>
    </contact_backup>
    <investigator>
      <last_name>Mariya N Davydova</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ekaterina Y Shevela, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 29, 2013</lastchanged_date>
  <firstreceived_date>April 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Siberian Branch of the Russian Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Ekaterina Y. Shevela</investigator_full_name>
    <investigator_title>Senior Researcher, Laboratory of Cellular Therapy, Research Institute of Clinical Immunology</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Intracranial Hemorrhages</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
